Drug-eluting stents for infrainguinal occlusive disease: progress and challenges.

High restenosis rate is still the major limitation of peripheral arterial interventions. Within the last years, drug-eluting stents have gained wide acceptance in the coronary arteries, however, these devices are not currently available for arteries outside the coronary vasculature. This article summarizes the special role of the superficial femoral artery in restenosis, with efforts being made to reduce the restenosis rate in this artery, focusing on stents and drug-eluting stents.

[1]  Thomas Zeller,et al.  Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. , 2005, Journal of vascular and interventional radiology : JVIR.

[2]  E. Minar,et al.  Primary Patency of Long-Segment Self-Expanding Nitinol Stents in the Femoropopliteal Arteries , 2005, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[3]  E. Atar,et al.  Balloon angioplasty of popliteal and crural arteries in elderly with critical chronic limb ischemia. , 2005, European journal of radiology.

[4]  Christopher Piorkowski,et al.  Prevalence and clinical impact of stent fractures after femoropopliteal stenting. , 2005, Journal of the American College of Cardiology.

[5]  A. Feiring,et al.  Primary stent-supported angioplasty for treatment of below-knee critical limb ischemia and severe claudication: early and one-year outcomes. , 2004, Journal of the American College of Cardiology.

[6]  F. Neumann,et al.  Percutaneous Peripheral Atherectomy of Femoropopliteal Stenoses Using a New-Generation Device: Six-Month Results from a Single-Center Experience , 2004, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[7]  L. Grenacher,et al.  PTA versus Stent bei Stenosen der A. femoralis und A. poplitea: Ergebnisse einer prospektiv randomisierten Multizenterstudie (REFSA) , 2004 .

[8]  W. O’Neill,et al.  Impact of Sirolimus-Eluting Stents on Outcome in Diabetic Patients: A SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) Substudy , 2004, Circulation.

[9]  Gregg W Stone,et al.  One-Year Clinical Results With the Slow-Release, Polymer-Based, Paclitaxel-Eluting TAXUS Stent: The TAXUS-IV Trial , 2004, Circulation.

[10]  A. Colombo,et al.  Polymer-Based Paclitaxel-Eluting Coronary Stents , 2004, Herz.

[11]  Charles L. Brown,et al.  Analysis of 1-Year Clinical Outcomes in the SIRIUS Trial: A Randomized Trial of a Sirolimus-Eluting Stent Versus a Standard Stent in Patients at High Risk for Coronary Restenosis , 2004, Circulation.

[12]  S. Silber.  Paclitaxel-eluting stents: are they all equal? An analysis of six randomized controlled trials in de novo lesions of 3,319 patients. , 2003, Journal of interventional cardiology.

[13]  William Wijns,et al.  Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS) , 2003, The Lancet.

[14]  S. Silber,et al.  Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions , 2003, Circulation.

[15]  J. Wiskirchen,et al.  Drug-eluting stents: potential applications for peripheral arterial occlusive disease. , 2003, Journal of vascular and interventional radiology : JVIR.

[16]  P. Serruys,et al.  Two-Year Angiographic and Intravascular Ultrasound Follow-Up After Implantation of Sirolimus-Eluting Stents in Human Coronary Arteries , 2003, Circulation.

[17]  Rossella Fattori,et al.  Drug-eluting stents in vascular intervention , 2003, The Lancet.

[18]  P. Serruys,et al.  Sirolimus-Eluting Stent for the Treatment of In-Stent Restenosis: A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study , 2003, Circulation.

[19]  Mary E. Russell,et al.  TAXUS I: Six- and Twelve-Month Results From a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions , 2003, Circulation.

[20]  E. Grube,et al.  Initial experience with paclitaxel-coated stents. , 2002, Journal of interventional cardiology.

[21]  M. Eisenberg,et al.  Coated stents for the prevention of restenosis: Part I. , 2002, Circulation.

[22]  Antonio Colombo,et al.  Mechanism of Late In-Stent Restenosis After Implantation of a Paclitaxel Derivate–Eluting Polymer Stent System in Humans , 2002, Circulation.

[23]  Gerhard Ziemer,et al.  Sirolimus-Eluting Stents for the Treatment of Obstructive Superficial Femoral Artery Disease: Six-Month Results , 2002, Circulation.

[24]  Renu Virmani,et al.  Morphological Predictors of Restenosis After Coronary Stenting in Humans , 2002, Circulation.

[25]  P. Serruys,et al.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.

[26]  R. Virmani,et al.  Histopathologic Alterations after Endovascular Radiation and Antiproliferative Stents: Similarities and Differences , 2002, Herz.

[27]  C. Claussen,et al.  Prophylaxis of Restenosis With 186Re-Labeled Stents in a Rabbit Model , 2001, Circulation.

[28]  G. Mintz,et al.  Prolonged Antiplatelet Therapy to Prevent Late Thrombosis After Intracoronary &ggr;-Radiation in Patients With In-Stent Restenosis: Washington Radiation for In-Stent Restenosis Trial Plus 6 Months of Clopidogrel (WRIST PLUS) , 2001, Circulation.

[29]  C. Claussen,et al.  Local Intra-Arterial Drug Delivery for Prevention of Restenosis: Comparison of the Efficiency of Delivery of Different Radiopharmaceuticals Through a Porous Catheter , 2001, Investigative radiology.

[30]  S. Cheng,et al.  Endovascular Stenting of Superficial Femoral Artery Stenosis and Occlusions: Results and Risk Factor Analysis , 2001, Cardiovascular surgery.

[31]  S. Soimakallio,et al.  Prospective trial of infrapopliteal artery balloon angioplasty for critical limb ischemia: angiographic and clinical results. , 2000, Journal of vascular and interventional radiology : JVIR.

[32]  F. Mahler,et al.  [Progress in endovascular therapy of peripheral arteries]. , 2000, Praxis.

[33]  P. Serruys,et al.  I like the candy, I hate the wrapper: the (32)P radioactive stent. , 2000, Circulation.

[34]  R. Virmani,et al.  Pathology of in-stent restenosis. , 1999, Current opinion in lipidology.

[35]  P. Serruys,et al.  Does angiography six months after coronary intervention influence management and outcome? Benestent II Investigators. , 1999, Journal of the American College of Cardiology.

[36]  S Marx,et al.  Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. , 1999, Circulation.

[37]  P. Teirstein,et al.  A subgroup analysis of the Scripps Coronary Radiation to Inhibit Proliferation Poststenting Trial. , 1998, International journal of radiation oncology, biology, physics.

[38]  A. Küttner,et al.  Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. , 1997, Circulation.

[39]  K. Kandarpa,et al.  Restenosis: pathophysiology and preventive strategies. , 1996, Journal of vascular and interventional radiology : JVIR.

[40]  C. Claussen,et al.  Covered stents for prevention of restenosis. Experimental and clinical results with different stent designs. , 1996, Investigative radiology.

[41]  Lippincott Williams Wilkins,et al.  Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angiopla , 1992, Circulation.

[42]  R. R. Murray,et al.  Long-segment femoropopliteal stenoses: is angioplasty a boon or a bust? , 1987, Radiology.

[43]  Stephan H. Duda,et al.  Sirolimus-Eluting Stents for the Treatment of Obstructive Superficial Femoral Artery Disease , 2003 .

[44]  K. Toutouzas,et al.  Sirolimus-eluting stents: a review of experimental and clinical findings , 2002, Zeitschrift für Kardiologie.

[45]  R. Virmani,et al.  Pathology of radiation-induced coronary artery disease in human and pig. , 1999, Cardiovascular radiation medicine.